Cor Vasa 2007, 49(4):147-151 | DOI: 10.33678/cor.2007.054

Prevention of cardiovascular complications with paroxetine in individuals with coronary heart disease and depressive/anxiety disorder. The PrevenPar project.

Milan Vrána
Praha, Česká republika

Results of clinical trials have confirmed that depressive/anxiety disorder as another cardiovascular risk factor. The risk is due to enhanced serotonin reuptake by the serotonin transporter. The reuptake not only blocks signal transmission within the brain, it also activates thrombocytes thereby raising the likelihood of thrombogenesis in the presence of coronary heart disease. Another factor affecting the degree of risk is the polymorphism of the serotonin transporter gene (5-HTTLPR) in its promoter segment (SLC6A4). The presence of a short allele (S) decreases the cardiovascular risk conversely increased by the presence of a long allele (L). Of all the currently known selective serotonin reuptake inhibitor (SSRI)-type antidepressants, paroxetine shows the highest affinity for the serotonin transporter. Transporter inhibition by paroxetine could thus make up for the effect of the gene polymorphism thereby reducing not only the degree of the depressive/anxiety disorder but, also, cardiovascular risk.
Our working hypothesis is currently being tested in a newly developed project called "PrevenPar". Eligible for inclusion are patients with coronary heart disease and a positive finding of a depressive, anxiety or depressive/anxiety disorder. Patients are to receive parallel state-of-the-art treatment by a cardiologist and by a psychiatrist with paroxetine. The primary goal of the PrevenPar project is to determine the success rate of treatment of the depressive/anxiety disorder with paroxetine. A secondary goal is to correlate the success/failure rates of cardiac treatment with the success/failure rates of psychiatric treatment. The PrevenPar project has been launched and involves general practitioners, cardiologists, and psychiatrists.
If successful, the project should provide guidance to eliminate the impact of the depressive/anxiety disorder, a newly identified cardiovascular risk factor.

Keywords: Depressive, anxiety disorder; Coronary heart disease; Cardiovascular risk; Serotonin transporter; Paroxetine; PrevenPar project

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrána M. Prevention of cardiovascular complications with paroxetine in individuals with coronary heart disease and depressive/anxiety disorder. The PrevenPar project. Cor Vasa. 2007;49(4):147-151. doi: 10.33678/cor.2007.054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rosengren A, Hawken S, Ovnpov S A, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 684 controls from 52 countries (the INTERHEART study): Case control study. Lancet 2004;364:953-62. Go to original source... Go to PubMed...
    2. Empana JP, Jouven X, Lemaitre RN, et al. Clinical depression and risk of out-of-hospital arrest. Arch Intern Med 2006;166:195-200. Go to original source... Go to PubMed...
    3. Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105:1049-53. Go to original source... Go to PubMed...
    4. Spijkerman TA, van den Brink RHS, May JF, et al. Decreased impact of postmyocardial infarction on cardiac prognosis. J Psychosom Res 2006;61:493-99. Go to original source... Go to PubMed...
    5. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as risk factor for mortality after coronary artery bypass surgery. Lancet 2003;362:604-9. Go to original source... Go to PubMed...
    6. Strik JJMH, Dennolet J, Lousberg R, Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 2003;42: 1801-7. Go to original source... Go to PubMed...
    7. Frazure-Smith N, Lespérance F. Reflections on depression as a cardiac risk factor. Psychosom Med 2005;67: S19-S25. Go to original source... Go to PubMed...
    8. Cífková R, Býma S, Češka R, a spol. Prevence kardiovaskulárních onemocnění v dospělém věku. Společná doporučení českých odborných společností. Vnitř Lék 2005;51:1021-36.
    9. Posener JA, De Battista Ch, Veldhuis JD, Province MA, Williams GH, Schatzberg AF. Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder. Psychoneuroendocrin 2004; 29:1129-37. Go to original source... Go to PubMed...
    10. Otte Ch, Marmar ChR, Pipkin SS, Moos R, Browner WS, Whooley MA. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: The Heart and Soul Study. Biol Psychiatry 2004;56:241-7. Go to original source... Go to PubMed...
    11. Lespérance F, Frazure-Smith N, Théroux P, Irwin M. The association between major depression and levels of soluble intercellular andhesion molecule 1, interleukine-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004;161:271-7. Go to original source... Go to PubMed...
    12. Otte Ch, Neylan TC, Pipkin SS, Browner WS, Whooley MA. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: Findings from the Heart and Soul Study. Am J Psychiatry 2005;2139-45. Go to original source... Go to PubMed...
    13. Carney RM, Blumenthal JA, Freedland KE, et al. Low heart rate variability and effect of depression on postmyocardial infarction mortality. Arch Intern Med 2005; 165:1486-91. Go to original source... Go to PubMed...
    14. Bruce EC, Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 2005;67:S34-S36. Go to original source... Go to PubMed...
    15. Tsao Ch-W, Lin Y-S, Chen Ch-Ch, Bai Ch-H, et al. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:899-905. Go to original source... Go to PubMed...
    16. Coto E, Reguero JR, Alvarez V, et al. 5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymophism in acute myocardial infarction. Clin Sci (Lond) 2003; 104:241-5. Go to original source... Go to PubMed...
    17. Fumeron F, Betoulle D, Nicaud V, et al. Serotonin transporter gene polymorphism and myocardial infarction. Circulation 2002;105:2943-5. Go to original source... Go to PubMed...
    18. Nakatani D, Sato H, Sakata Y, et al. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiace events after acute myocardial infarction. Am Heart J 2005;150:652-8. Go to original source... Go to PubMed...
    19. Fumeron F, Betoulle D, Aubert R, et al. Association of a functional 5-HT transporter gene polymorphism with anorexia nerviosa and food intake. Mol Psychiatry 2001;6:1-916. Go to original source... Go to PubMed...
    20. Murphy GM, Hollander SB, Rodriges HE, et al. Effect of serotonin transporter gene promoter polymorphism on myrtazapine and paroxetine efficacy and adverse events in geriateric depression. Arch Gern Psychiatry 2004; 61:1163-9. Go to original source... Go to PubMed...
    21. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline antidepressant medication heart attact randomized trial (SADHART). Am Heart J 1999;137:1110-7.
    22. Taylor BC, Youngblood ME, Catellier D, et al. Effect of antidepressant medication on morbidity and mortality in depressed patients. Arch Gen Psychiatry 2005;62:792-8. Go to original source... Go to PubMed...
    23. Vermeten E, Vythilingam M, Schmahl Ch, et al. Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorders. Ann NY Acad Sci 2006;1071:184-202. Go to original source... Go to PubMed...
    24. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64:250-8. Go to original source... Go to PubMed...
    25. Sheenan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine treatment of panic disorder. J Clin Psychiatry 2005;66:34-40. Go to original source...
    26. Pollock BG, Fouzia L-T, Wagner W. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40. Go to original source... Go to PubMed...
    27. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-6. Go to original source... Go to PubMed...
    28. Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system and coronary disease. Psychosom Med 2005;67:S29-S33. Go to original source... Go to PubMed...
    29. Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 2002;52:418-29. Go to original source... Go to PubMed...
    30. Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: A review of literature. Pharmacotherapy 2003;23:754-71. Go to original source... Go to PubMed...
    31. Vrána M, Honzák R. Lze snížit kardiovaskulární riziko při ischemické chorobě srdeční léčbou deprese? Farmakoterapie 2006;3:318-22.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes